谷歌浏览器插件
订阅小程序
在清言上使用

2122 Treatment Outcomes According to Extended RAS Mutation Testing in a Phase II Study of First-Line Mfolfox Plus Cetuximab Followed by Cetuximab in Monotherapy As Maintenance Therapy or Mfolfox Plus Cetuximab in Patients with Metastatic Colorectal Cancer: the MACRO-2 Trial

EUROPEAN JOURNAL OF CANCER(2015)

引用 1|浏览61
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要